Exercise and Diabetes Interventions to Improve Brain Health in Older Adults With Type 2 Diabetes
- Sponsor
- Western University, Canada
- Study ID
- NCT07485062
- Phase
- PHASE4
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Cognitive Decline in Older Adults
- Type 2 Diabetes
Eligibility Criteria
- Sex
- ALL
- Age
- 65 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- semaglutide — DRUGInjectable semaglutide administered once weekly by subcutaneous injection for 16 weeks, as prescribed and monitored by the study physician.
- Moderate-Intensity Resistance Exercise — BEHAVIORALSupervised moderate-intensity resistance exercise training performed three times per week for 32 weeks.
- Balance and Tone (BAT) Exercise — BEHAVIORALSupervised balance-and-tone (BAT) exercise performed three times per week for 32 weeks, serving as an active control exercise condition.
Study Details
Type 2 diabetes and low levels of physical activity are associated with an increased risk of cognitive decline in older adults. Improving blood sugar control and engaging in regular exercise may help support brain health and physical function in this population. The MOTIVATE study is a randomized clinical trial designed to examine the effects of supervised exercise and diabetes treatment with semaglutide, alone or in combination, on cognitive function, physical health, and brain-related outcomes in older adults with Type 2 diabetes. Participants will be assigned to one of four study groups involving exercise training, control exercise, semaglutide treatment, or standard diabetes care. Participants will complete supervised exercise sessions three times per week for 32 weeks, with some participants also receiving weekly semaglutide injections for 16 weeks. Assessments will include cognitive testing, physical and functional measures, blood-based metabolic markers, and brain imaging. This study aims to improve understanding of how exercise and diabetes treatments may support brain health in older adults with Type 2 diabetes.
Key Dates
- Start date
- May 1, 2026
- Status verified
- Mar 2026
- Primary completion
- May 1, 2029
- Completion
- May 1, 2029
Study Design
- Enrollment
- 164 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- FACTORIAL
- Primary purpose
- TREATMENT
Arms
- Experimental: Resistance Exercise + SemaglutideParticipants assigned to this arm will receive injectable semaglutide once weekly for 16 weeks, in addition to participating in supervised moderate-intensity resistance exercise training three times per week for 32 weeks. Semaglutide will be administered during the first 16 weeks, followed by a 16-week exercise-only period.
- Active Comparator: Standard of Care + Resistance ExerciseParticipants assigned to this arm will receive standard of care treatment for Type 2 diabetes for 16 weeks and participate in supervised moderate-intensity resistance exercise training three times per week for 32 weeks. No semaglutide will be administered during the study period.
- Active Comparator: Semaglutide + Balance and Tone ExerciseParticipants assigned to this arm will receive injectable semaglutide once weekly for 16 weeks and participate in supervised balance-and-tone (BAT) exercise three times per week for 32 weeks. Semaglutide will be administered during the first 16 weeks, followed by a 16-week exercise-only period.
- Active Comparator: Standard of Care + Balance and Tone ExerciseParticipants assigned to this arm will receive standard of care treatment for Type 2 diabetes for 16 weeks and participate in supervised balance-and-tone (BAT) exercise three times per week for 32 weeks. No semaglutide will be administered during the study period.
Primary Outcome Measure
Trail Making Test (TMT) Part A and B [ Time Frame: Baseline (Week 0), Midpoint (Week 16), Endpoint (Week 32) ]
Central Contacts
- Olivia Ghosh-Swaby, PhD5196612111
Related Studies
- Evaluation of Superiority of Valsartan+Celecoxib+Metformin Over Metformin Alone in Type 2 Diabetes PatientsPHASE1/PHASE2 · Not Yet Recruiting · ARKAY Therapeutics · Albany, New York
- The Role of Type 2 Diabetes on Skeletal Muscle Atrophy and Recovery Following Bed Rest in Older AdultsRecruiting · AdventHealth Translational Research Institute · Orlando, Florida
- Sleep and Glycemic Control in Type 2 Diabetes AdolescentsRecruiting · Children's Hospital of Philadelphia · Philadelphia, Pennsylvania
- Brown Adipose Tissue Activation by Spinal Cord StimulationRecruiting · Oregon Health and Science University · Portland, Oregon